Indivior Pharmaceuticals, Inc. (INDV) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Indivior Pharmaceuticals, Inc.'s filing signal turned positive.

Indivior Pharmaceuticals, Inc. is a leading global pharmaceutical company focused on opioid use disorder (OUD) treatments, holding a dominant position in the long-acting injectable (LAI) market with its flagship product, SUBLOCADE. The company's core strategy revolves around evidence-based pharmacotherapies for OUD, aiming to advance the neurobiological understanding of the disease. Indivior's primary market is the United States, which accounted for approximately 85% of its net revenues in 2025, with additional product availability in Canada, Australia, France, and Germany. The company has undergone a significant corporate reorganization, changing its domicile from the UK to the U.S. effective January 2026.

Revenue is primarily driven by sales of SUBLOCADE, a long-acting injectable buprenorphine treatment for OUD, and other buprenorphine-based sublingual products like SUBOXONE Film. The U.S. market represents the vast majority of net revenue.